Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

CYP450-based reclassification of urinary metabolic ratio cutoffs for pain management and substance abuse treatment drugs.

Journal of opioid management - 1 Jan 2025

Pesce Amadeo J, Cua Agnes, Wickett Eugene

Abstract excerpt

Traditional 95 percent reference intervals (RIs) for urinary metabolic ratios (MRs) are useful for identifying unusually slow or fast metabolism, but these do not account for cytochrome P450 (CYP450)-mediated variability in drug metabolism. In this study, we re-evaluated MR cutoff limits for 18 metabolite-parent drug pairs using genotype-predicted phenotype frequencies reported by Zhu et al. These pairs include...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Analgesics, Opioid
Share to Cytochrome P-450 Enzyme System

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to CYP2C9 gene

Share to CYP3A4 gene

Share to Genotype

Share to Phenotype

Share to Substance-Related Disorders

Source

Identifiers

PMID: 42429026
DOI: 10.5055/jom.1001

Genes

CYP2B6
CYP2C19
CYP2C9
CYP3A4

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

CYP450-based reclassification of urinary metabolic ratio cutoffs for pain management and substance abuse treatment drugs.PMID 42429026Read ↗

Therapeutic Drug Monitoring of Psychotropics as a Diagnostic Tool for CYP2D6 Poor Metabolizer Phenotype.Semantic proximity Read ↗

Complications of Psychotropic and Pain Medications in an Ultrarapid Metabolizer Patient at the Upper 1% of Cytochrome P450 (CYP450) Function Quantified by Combinatorial CYP450 Genotyping.Semantic proximity Read ↗

CYP2D6 Phenotypes and Emergency Department Visits Among Patients Receiving Opioid Treatment.Semantic proximity Read ↗

Sex Differences in Associations Between CYP2D6 Phenotypes and Response to Opioid AnalgesicsSemantic proximity Read ↗

Physiologically based pharmacokinetic modeling of tramadol to inform dose adjustment and drug-drug interactions according to CYP2D6 phenotypes.Semantic proximity Read ↗

Contribution of CYP2D6 Functional Activity to Oxycodone Efficacy in Pain Management: Genetic Polymorphisms, Phenoconversion, and Tissue-Selective MetabolismSemantic proximity Read ↗

In vitro comparative analysis of metabolic capabilities and inhibitory profiles of selected CYP2D6 alleles on tramadol metabolism.Semantic proximity Read ↗

Evaluation of analytical and clinical performance of a dual-probe phenotyping method for CYP2D6 polymorphism and CYP3A4 activity screening.Semantic proximity Read ↗

Impact of genetic variation in CYP2C19, CYP2D6, and CYP3A4 on oxycodone and its metabolites in a large database of clinical urine drug tests.Semantic proximity Read ↗

Utilization of pharmacogenomics and therapeutic drug monitoring for opioid pain management.Semantic proximity Read ↗

Use of midazolam urinary metabolic ratios for cytochrome P450 3A (CYP3A) phenotyping.Semantic proximity Read ↗

Functional phenotyping of the CYP2D6 probe drug codeine in the horse.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.